BioSpace News Archive

McKesson Corporation announced that the McKesson board of directors elected James H. Hinton and Kathleen Wilson-Thompson as directors on Jan. 13, 2022.

Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has enrolled the first subject in the phase II/III study (Tau NexGen study).

ImmVira’s breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good safety and tolerability results.

BrainChip Holdings Ltd announced that the US Patents and Trademarks Office has issued BrainChip US Patent 11,227,210 “Event-based Classification of Features in a Reconfigurable and Temporally Coded Convolutional Spiking Neural Network.”

On December 7, 2021, MIOK Keratoprosthesis was approved for listing by NMPA, the Chinese agency for regulating drugs and medical devices.

Positive reimbursement strategies by governments and key players for medical gadgets and instruments are anticipated to help the development of the market over the forthcoming years.

Surge in prevalence of chronic diseases including diabetic foot ulcers among diabetic patients across the globe is creating revenue-generation opportunities in the global diabetic foot ulcers and pressure ulcers market.

The overall cell expansion market is expanding wide improvement essentially as a result of the unfathomable power of steady infirmities, which further extends the prerequisite for use of cell expansion-based methodology.

The global bladder scanners market is prognosticated to gain a valuation of US$ 210.0 Mn by 2026. Thus, the market is estimated to expand at a CAGR of 5.8% during the forecast period of 2018 to 2026.